C12N2760/18762

RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINS

A recombinant, attenuated mumps virus is described. The recombinant virus is based on the genotype A Jeryl Lynn vaccine strain, but is modified to express genotype G consensus fusion (F) and hemagglutinin-neuraminidase (HN) proteins. The recombinant virus optionally includes a mutation that prevents expression of viral protein V. The recombinant mumps virus can be used as a vaccine to inhibit mumps virus infection and the development of mumps disease.

Recombinant mumps virus vaccine

The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV.sup.Iowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuV.sup.Iowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVΔSH) and/or incapable of expressing the V protein (rMuVΔV).

RECOMBINANT MUMPS VIRUS VACCINE
20190216918 · 2019-07-18 ·

The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV.sup.Iowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuV.sup.Iowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVSH) and/or incapable of expressing the V protein (rMuVV).

RECOMBINANT MUMPS VIRUS VACCINE
20170232098 · 2017-08-17 ·

The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV.sup.Iowa/US/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to rMuV.sup.Iowa/US/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVSH) and/or incapable of expressing the V protein (rMuVV).

Vaccine prepared utilizing human parainfluenza virus type 2 vector

Disclosed are: a virus vector in which a gene encoding an antigenic polypeptide is integrated in human parainfluenza virus type 2 gene, wherein the antigenic polypeptide is expressed in the form of a fusion protein with a viral structural protein; and a method for producing the same. The virus vector of the present invention contains a quantitatively large amount of the antigenic peptide on the virus particle and can efficiently deliver the antigenic polypeptide to a target cell.

Recombinant mumps virus vaccine

The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuV.sup.Iowa/us/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to MuV.sup.Iowa/us/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuVSH) and/or incapable of expressing the V protein (rMuVV).